{"id":51389,"date":"2016-01-26T08:42:01","date_gmt":"2016-01-26T13:42:01","guid":{"rendered":"http:\/\/www.hedgeco.net\/news\/?p=51389"},"modified":"2016-01-26T08:42:01","modified_gmt":"2016-01-26T13:42:01","slug":"hedge-fund-kerrisdale-shorts-zafgen-sends-stock-tumbling","status":"publish","type":"post","link":"https:\/\/hedgeco.net\/news\/01\/2016\/hedge-fund-kerrisdale-shorts-zafgen-sends-stock-tumbling.html","title":{"rendered":"Hedge Fund Kerrisdale Shorts Zafgen, Sends Stock Tumbling"},"content":{"rendered":"<p>\n(Reuters) Biopharmaceutical company Zafgen&#8217;s stock tumbled as much as 11.5 percent in early trading on Monday after hedge fund Kerrisdale Capital said it has a short bet on the stock, arguing that U.S. regulators will not approve the sale of its obesity drug.&#8221;Zafgen&#8217;s deadly obesity drug (beloranib) has no reasonable chance of FDA approval,&#8221; the hedge fund wrote in an 11-page report issued on Monday, adding that the company&#8217;s stock price is worth only $3 a share. <\/p>\n<p><a href=\"http:\/\/in.reuters.com\/article\/zafgen-kerrisdale-idINL2N1590PC\">To read this article:<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>(Reuters) Biopharmaceutical company Zafgen&#8217;s stock tumbled as much as 11.5 percent in early trading on Monday after hedge fund Kerrisdale Capital said it has a short bet on the stock, arguing that U.S. regulators will not approve the sale of [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[],"class_list":["post-51389","post","type-post","status-publish","format-standard","hentry","category-syndicated"],"_links":{"self":[{"href":"https:\/\/hedgeco.net\/news\/wp-json\/wp\/v2\/posts\/51389","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/hedgeco.net\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/hedgeco.net\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/hedgeco.net\/news\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/hedgeco.net\/news\/wp-json\/wp\/v2\/comments?post=51389"}],"version-history":[{"count":1,"href":"https:\/\/hedgeco.net\/news\/wp-json\/wp\/v2\/posts\/51389\/revisions"}],"predecessor-version":[{"id":51390,"href":"https:\/\/hedgeco.net\/news\/wp-json\/wp\/v2\/posts\/51389\/revisions\/51390"}],"wp:attachment":[{"href":"https:\/\/hedgeco.net\/news\/wp-json\/wp\/v2\/media?parent=51389"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/hedgeco.net\/news\/wp-json\/wp\/v2\/categories?post=51389"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/hedgeco.net\/news\/wp-json\/wp\/v2\/tags?post=51389"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}